NYSE:BVS

Bioventus News Headlines

$14.55
+0.46 (+3.26 %)
(As of 05/6/2021 04:30 PM ET)
Add
Compare
Today's Range
$14.00
$14.67
50-Day Range
$13.75
$16.31
52-Week Range
$10.74
$19.51
Volume87,909 shs
Average Volume237,424 shs
Market Capitalization$826.80 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Headlines

Bioventus (NYSE BVS) News Headlines Today

SourceHeadline
Bioventus (BVS) Scheduled to Post Earnings on WednesdayBioventus (BVS) Scheduled to Post Earnings on Wednesday
americanbankingnews.com - May 5 at 2:08 AM
Bioventus (NYSE:BVS) Shares Gap Down to $14.40Bioventus (NYSE:BVS) Shares Gap Down to $14.40
americanbankingnews.com - May 3 at 12:04 PM
Bioventus (NYSE:BVS) Trading Up 4.2%Bioventus (NYSE:BVS) Trading Up 4.2%
americanbankingnews.com - April 28 at 12:38 PM
Bioventus Announces First Commercial Shipment of the Bioness(R) Integrated Therapy System (BITS) Balance SystemBioventus Announces First Commercial Shipment of the Bioness(R) Integrated Therapy System (BITS) Balance System
marketwatch.com - April 28 at 10:02 AM
Bioventus Announces First Commercial Shipment of the Bioness® Integrated Therapy System (BITS) Balance SystemBioventus Announces First Commercial Shipment of the Bioness® Integrated Therapy System (BITS) Balance System
finance.yahoo.com - April 27 at 8:44 AM
Bioventus (NYSE:BVS) Price Target Raised to $19.00 at Morgan StanleyBioventus (NYSE:BVS) Price Target Raised to $19.00 at Morgan Stanley
americanbankingnews.com - April 26 at 9:58 AM
Bioventus (NYSE:BVS) Stock Price Down 2.8%Bioventus (NYSE:BVS) Stock Price Down 2.8%
americanbankingnews.com - April 21 at 1:38 PM
Bioventus (NYSE:BVS) Trading 4.9% Higher  After Analyst UpgradeBioventus (NYSE:BVS) Trading 4.9% Higher After Analyst Upgrade
americanbankingnews.com - April 20 at 1:18 PM
Bioventus (NYSE:BVS) Shares Gap Down to $14.77Bioventus (NYSE:BVS) Shares Gap Down to $14.77
americanbankingnews.com - April 19 at 12:02 PM
Morgan Stanley Raises Bioventus (NYSE:BVS) Price Target to $19.00Morgan Stanley Raises Bioventus (NYSE:BVS) Price Target to $19.00
americanbankingnews.com - April 19 at 10:28 AM
Bioventus to Release First Quarter of Fiscal Year 2021 Financial Results on May 12, 2021Bioventus to Release First Quarter of Fiscal Year 2021 Financial Results on May 12, 2021
finance.yahoo.com - April 12 at 8:08 PM
Bioventus makes multimillion-dollar acquisitionBioventus makes multimillion-dollar acquisition
bizjournals.com - March 31 at 12:58 PM
Bioventus Acquires Bioness, Inc.Bioventus Acquires Bioness, Inc.
finance.yahoo.com - March 30 at 8:34 PM
Bioventus’ 4Q Results Outperform Analysts’ ExpectationsBioventus’ 4Q Results Outperform Analysts’ Expectations
finance.yahoo.com - March 26 at 6:47 AM
Bioventus, Inc. Class A to Host Earnings CallBioventus, Inc. Class A to Host Earnings Call
finance.yahoo.com - March 25 at 7:50 PM
Bioventus Inc. Reports Fourth Quarter and Full Year 2020 Financial Results; Introduces Full Year 2021 Financial GuidanceBioventus Inc. Reports Fourth Quarter and Full Year 2020 Financial Results; Introduces Full Year 2021 Financial Guidance
finance.yahoo.com - March 25 at 7:50 PM
Bioventus Inc. Cl ABioventus Inc. Cl A
marketwatch.com - March 18 at 12:46 PM
Bioventus Reports First Patients Enrolled in Phase 1 Clinical Trial of MOTYS(TM) (PTP-001) for the Treatment of Knee OABioventus Reports First Patients Enrolled in Phase 1 Clinical Trial of MOTYS(TM) (PTP-001) for the Treatment of Knee OA
marketwatch.com - March 11 at 6:47 PM
Bioventus Reports First Patients Enrolled in Phase 1 Clinical Trial of MOTYS™ (PTP-001) for the Treatment of Knee OABioventus Reports First Patients Enrolled in Phase 1 Clinical Trial of MOTYS™ (PTP-001) for the Treatment of Knee OA
finance.yahoo.com - March 11 at 1:46 PM
This page was last updated on 5/6/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.